Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17171857 | 1.00 | POLB (0.37) | POLBKMT2AMEN1NPC1NFKB1 | |
| SCHEMBL17171855 | 0.89 | POLB (0.35) | POLBKMT2AMEN1NPC1NFKB1 | |
| SCHEMBL8620112 | 0.89 | POLB (0.35) | POLBKMT2AMEN1NPC1NFKB1 | |
| SCHEMBL8620116 | 0.89 | POLB (0.35) | POLBKMT2AMEN1NPC1NFKB1 | |
| SCHEMBL6773084 | 0.82 | SPR (0.33) | POLBKMT2AMEN1NPC1NFKB1 | |
| SCHEMBL8544565 | 0.79 | POLB (0.46) | POLBKMT2AMEN1NPC1NFKB1 | |
| SCHEMBL8544568 | 0.79 | POLB (0.46) | POLBKMT2AMEN1NPC1NFKB1 | |
| SCHEMBL6773451 | 0.78 | POLB (0.31) | POLB | |
| SCHEMBL6773447 | 0.78 | POLB (0.31) | POLB | |
| SCHEMBL8460273 | 0.76 | POLB (0.32) | POLBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291570-A1 | Substituted N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides | BASF SE (DE) | 2015-10-15 | — | — | US | disclosed |
| WO-2013076315-A2 | SUBSTITUTED N-(TETRAZOL-5-YL)- AND N-(TRIAZOL-5-YL)ARYLCARBOXAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291570-A1 | Substituted N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides | CYCS, CYC1, CBR3 | POLB 2116/4885KMT2A 1374/4885MEN1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.